FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALSGlobeNewsWire • 07/26/22
Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/25/22
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/20/22
Alzheimer's Drug Is Up for Accelerated Approval. Outlook for Biogen, Eisai Is Uncertain.Barrons • 07/06/22